Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries

References

• Futterweit W, Mechanick JL. Polycystic ovarian disease: etiology, diagnosis and treatment. Comp Ther 1988; 14: 12–20
   PubMedGoogle Scholar
• Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853–61
   PubMed Web of Science ®Google Scholar
• Robinson S, Kiddy D, Gelding SV, et al. The relationship of insulin sensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol 1993; 39: 351–5
   PubMed Web of Science ®Google Scholar
• Francis C, Marder V. Mechanisms of fibrinolysis. Williams Haematology, E Beutler, M Licthman, B Coller, et al. McGraw-Hill, New York 1995; 1252–60
   Google Scholar
• Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochem Biophys Acta 1985; 823: 35–65
   PubMed Web of Science ®Google Scholar
• Beers WH. Follicular plasminogen and plasminogen activator and the effect of plasmin on ovarian follicle wall. Cell 1975; 6: 379–86
   PubMedGoogle Scholar
• Piquette GN, Crabtree ME, Imam E-D, et al. Regulation of plasminogen activator inhibitor-1 and -2 messenger ribonucleic acid levels in human cumulus and granulosa–luteal cells. J Clin Endocrinol Metab 1993; 76: 518–28
   PubMedGoogle Scholar
• Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Rev 1990; 9: 289–303
   PubMed Web of Science ®Google Scholar
• Dahlgren E, Jansen OP, Johansson S, et al. Haemostatic and metabolic variables in women with the polycystic ovary syndrome. Fertil Steril 1994; 61: 455–9
   PubMed Web of Science ®Google Scholar
• Anderson P, Seljeflot I, Abdelnoor M, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metab Clin Exp 1995; 44: 611–16
   PubMedGoogle Scholar
• Sampson M, Kong C, Patel A, et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996; 45: 623–9
   PubMed Web of Science ®Google Scholar
• Atiomo WU, Bates SA, Condon JE, et al. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 236–41
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I, Kooistra T, et al. Insulin stimulates synthesis of plasminogen activator inhibitor 1 by the human hepatocellular cell line Hep G2. Thromb Haemost 1988; 60: 491–4
   PubMed Web of Science ®Google Scholar
• Velazquez EM, Mendoza SG, Wang P, et al. Metformin therapy is associated with a decrease in plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metab Clin Exp 1997; 46: 454–7
   PubMed Web of Science ®Google Scholar
• Dahlgren E. Johansson S, Linstedt G, et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long term follow-up focusing on natural history and circulating hormones. Fertil Steril 1992; 57: 505–13
   PubMed Web of Science ®Google Scholar
• Hsu S, Raine L, Fanger H. Use of avidin–biotin–peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–80
   PubMed Web of Science ®Google Scholar
• Whawell SA, Wang Y, Fleming K, et al. Localization of plasminogen activator inhibitor-1 in inflamed appendix by in-situ hybridisation. J Pathol 1993; 169: 67–71
   PubMed Web of Science ®Google Scholar
• Estelles A, Gilabert J, Keeton M, et al. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143–50
   PubMedGoogle Scholar
• Van der Loos CM, Monique MH, Marijaianowski H, et al. Quantification in immunohistochemistry: the measurement of the ratios of collagen types I and III. Histochem J 1994; 26: 347–54
   PubMedGoogle Scholar
• Taymor ML. The regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertil Steril 1996; 65: 235–47
   PubMed Web of Science ®Google Scholar
• Hughesdon PE. Morphology and morphogenesis of the Stein–Leventhal ovary and so-called ‘hyperthecosis’. Obstet Gynecol Surv 1982; 37: 57–77
   Google Scholar
• Fauser BC. Observations in favor of normal early follicle development and disturbed dominant follicle selection in polycystic ovary syndrome. Gynecol Endocrinol 1994; 8: 75–82
   PubMedGoogle Scholar
• Louvert JP, Harman SM, Schreiber JR, et al. Evidence for the role of androgens in follicular maturation. Endocrinology 1975; 97: 366–72
   PubMedGoogle Scholar
• Gregory F, Enckson AJW, Hsueh ME, et al. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. J Clin Endocrinol Metab 1979; 49: 514–19
   PubMedGoogle Scholar
• Giudice LC, Van Dessel HJ, Cataldo NA, et al. Circulating and ovarian IGF binding proteins: potential roles in normo-ovulatory cycles and in polycystic ovarian syndrome. Prog Growth Factor Res 1995; 62: 397–408
   Google Scholar
• Roberts VJ, Barth S, el-Roeiy A, et al. Expression of inhibin/activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. J Clin Endocrinol Metab 1994; 75: 1434–9
   Google Scholar
• Palumbo A, Pourmotabbed G, Carcangiu ML, et al. Immunohistochemical localization of renin and angiotensin in the ovary: comparison between normal women and patients with histologically proven polycystic ovarian disease. Fertil Steril 1993; 60: 280–4
   PubMedGoogle Scholar
• Peng X-R, Hsueh AJW, Tor NY. Transient and cell specific expression of tissue type plasminogen activator and plasminogen-activator-inhibitor type 1 results in controlled and directed proteolysis during gonadotrophin-induced ovulation. Eur J Biochem 1993; 214: 147–56
   PubMedGoogle Scholar
• Padayatty SJ, Orme S, Zenobi PD, et al. The effects of insulin-like growth factor 1 on plasminogen activator inhibitor-1 synthesis and secretion: results from in vitro and in vivo studies. Thromb Haemost 1993; 70: 1009–13
   PubMed Web of Science ®Google Scholar
• Nguyen G, Delarue F, Berrou J, et al. Specific receptor binding of renin on mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996; 50: 1897–903
   PubMed Web of Science ®Google Scholar
• Piquette G, Simon C, Danaouri IE, et al. Gene regulation of interleukin-1 B, interleukin-1 receptor type 1, and plasminogen activator inhibitor-1 and -2 in human granulosa-luteal cells. Fertil Steril 1994; 62: 760–70
   PubMedGoogle Scholar